Reconsidering the latent structure of negative symptoms in schizophrenia: A review of evidence supporting the 5 consensus domains

Abstract

Negative symptoms have featured prominently as a core symptom of schizophrenia (SZ) since the earliest descriptions of the disorder.1,2 They predict a range of poor clinical outcomes, such as reduced rates of recovery,3 poor functional outcome,4 lower subjective well-being,5 and liability for the onset of a psychotic disorder.6 Unfortunately, interventions targeting negative symptoms have produced minimal benefits and no drug has received US Food and Drug Administration approval for an indication of negative symptoms.7